Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1954 1
1955 2
1957 1
1973 1
1984 1
1985 2
1986 1
1987 2
1988 3
1989 6
1990 6
1991 6
1992 3
1993 5
1994 3
1995 4
1996 5
1997 5
1998 7
1999 10
2000 11
2001 12
2002 10
2003 10
2004 8
2005 5
2006 12
2007 14
2008 13
2009 7
2010 10
2011 10
2012 14
2013 18
2014 26
2015 17
2016 15
2017 15
2018 16
2019 9
2020 11
2021 22
2022 15
2023 21
2024 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

381 results

Results by year

Filters applied: . Clear all
Page 1
Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G; SERAPHIN Investigators. Pulido T, et al. N Engl J Med. 2013 Aug 29;369(9):809-18. doi: 10.1056/NEJMoa1213917. N Engl J Med. 2013. PMID: 23984728 Free article. Clinical Trial.
CONCLUSIONS: Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study. (Funded by Actelion Pharmaceuticals; SERAPHIN ClinicalTrials.gov number, NCT00660179.)....
CONCLUSIONS: Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driv …
The impact of vitamin D on cancer: A mini review.
Seraphin G, Rieger S, Hewison M, Capobianco E, Lisse TS. Seraphin G, et al. J Steroid Biochem Mol Biol. 2023 Jul;231:106308. doi: 10.1016/j.jsbmb.2023.106308. Epub 2023 Apr 11. J Steroid Biochem Mol Biol. 2023. PMID: 37054849 Free PMC article. Review.
Reply to Seraphin.
Moiroux N, Pennetier C, Corbel V. Moiroux N, et al. J Infect Dis. 2013 Apr;207(7):1184-5. doi: 10.1093/infdis/jit012. Epub 2013 Jan 10. J Infect Dis. 2013. PMID: 23307934 No abstract available.
Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension.
Souza R, Delcroix M, Galié N, Jansa P, Mehta S, Pulido T, Rubin L, Sastry BKS, Simonneau G, Sitbon O, Torbicki A, Boyanova N, Chamitava L, Stein C, Channick RN. Souza R, et al. Adv Ther. 2022 Sep;39(9):4374-4390. doi: 10.1007/s12325-022-02199-x. Epub 2022 Jul 12. Adv Ther. 2022. PMID: 35819570 Free PMC article. Clinical Trial.
METHODS: Patients in SERAPHIN who completed the double-blind treatment period or experienced a morbidity event during the study could enter SERAPHIN OL. ...RESULTS: Of 742 patients randomised in SERAPHIN, 550 (74.1%) entered SERAPHIN OL (OL safety set) …
METHODS: Patients in SERAPHIN who completed the double-blind treatment period or experienced a morbidity event during the study could …
Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.
Jansa P, Pulido T. Jansa P, et al. Am J Cardiovasc Drugs. 2018 Feb;18(1):1-11. doi: 10.1007/s40256-017-0260-1. Am J Cardiovasc Drugs. 2018. PMID: 29280064 Free PMC article. Review.
SERAPHIN was a double-blind, placebo-controlled, event-driven phase III trial that evaluated the effects of long-term treatment with macitentan, an oral endothelin receptor antagonist, in patients with pulmonary arterial hypertension (PAH). ...The safety profile of maciten …
SERAPHIN was a double-blind, placebo-controlled, event-driven phase III trial that evaluated the effects of long-term treatment with …
Seraphin (1747-1800), "the facetious hunchback": How ankylosing spondylitis contributed to the success of his shadow puppet theatre.
Prati C, Verhoeven F, Wendling D, Quetel E. Prati C, et al. Rheumatol Int. 2024 Nov 13. doi: 10.1007/s00296-024-05739-6. Online ahead of print. Rheumatol Int. 2024. PMID: 39535600
Andre Leri, a pupil of Pierre Marie, hypothesized from skeletal analysis that Seraphin must have suffered from rhizomelic spondylosis (the first french name for ankylosing spondylitis). ...These documents show how this deforming disease contributed to the success of Ser …
Andre Leri, a pupil of Pierre Marie, hypothesized from skeletal analysis that Seraphin must have suffered from rhizomelic spondylosis …
[The SERAPHIN study].
D'Alto M, Vitulo P. D'Alto M, et al. G Ital Cardiol (Rome). 2015 Jan;16(1):6-10. doi: 10.1714/1776.19238. G Ital Cardiol (Rome). 2015. PMID: 25689745 Italian. No abstract available.
381 results